COMPANION ANIMAL TREATMENTS

Provided herein are injectable pharmaceutical formulations, methods for their production, kits, and uses thereof in the treatment of disorders such as mental disorders in subjects such as companion animals. The injectable pharmaceutical formulations include a psychopharmaceutical agent, a release mo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SHUKOOR, Mohammed I, MORGAN, Michael E, VARTY, Geoffrey B, DRYSDALE, Doug, PALFREYMAN, Michael, NIVOROZHKIN, Alex, AVERY, Kenneth L, FENG, Ju, PATHARE, Pradip M
Format: Patent
Sprache:eng ; fre
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator SHUKOOR, Mohammed I
MORGAN, Michael E
VARTY, Geoffrey B
DRYSDALE, Doug
PALFREYMAN, Michael
NIVOROZHKIN, Alex
AVERY, Kenneth L
FENG, Ju
PATHARE, Pradip M
description Provided herein are injectable pharmaceutical formulations, methods for their production, kits, and uses thereof in the treatment of disorders such as mental disorders in subjects such as companion animals. The injectable pharmaceutical formulations include a psychopharmaceutical agent, a release modifier, and an aqueous vehicle. The pharmaceutical formulations allow for a time-restricted temporal controlled-release of the psychopharmaceutical agent upon administration by injection such as subcutaneous injection. The mental disorders treatable with the pharmaceutical formulations include those associated with a 5-HT2 receptor, such as anxiety disorders (e.g., separation anxiety, social anxiety, noise phobia, obsessive-compulsive disorder (OCD)) and depressive disorders. L'invention concerne des formulations pharmaceutiques injectables, des procédés de production, des trousses et leur utilisation dans le traitement de troubles tels que les troubles mentaux chez des sujets tels que les animaux de compagnie. Les formulations pharmaceutiques injectables comprennent un agent psychopharmaceutique, un modificateur de libération et un véhicule aqueux. Les formulations pharmaceutiques permettent une libération contrôlée temporelle limitée dans le temps de l'agent psychopharmaceutique lors de l'administration par injection, par exemple sous-cutanée. Les troubles mentaux pouvant être traités par les formulations pharmaceutiques comprennent ceux associés à un récepteur 5-HT2, tels que les troubles anxieux (p. ex., l'anxiété de séparation, l'anxiété sociale, la phobie du bruit, les troubles obsessionnels compulsifs [TOC]) et les troubles dépressifs.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2024251807A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2024251807A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2024251807A13</originalsourceid><addsrcrecordid>eNrjZJB29vcNcPTz9PdTAJK-jj4KIUGujiG-rn4hwTwMrGmJOcWpvFCam0HZzTXE2UM3tSA_PrW4IDE5NS-1JD7c38jAyMTI1NDCwNzR0Jg4VQDehSGN</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMPANION ANIMAL TREATMENTS</title><source>esp@cenet</source><creator>SHUKOOR, Mohammed I ; MORGAN, Michael E ; VARTY, Geoffrey B ; DRYSDALE, Doug ; PALFREYMAN, Michael ; NIVOROZHKIN, Alex ; AVERY, Kenneth L ; FENG, Ju ; PATHARE, Pradip M</creator><creatorcontrib>SHUKOOR, Mohammed I ; MORGAN, Michael E ; VARTY, Geoffrey B ; DRYSDALE, Doug ; PALFREYMAN, Michael ; NIVOROZHKIN, Alex ; AVERY, Kenneth L ; FENG, Ju ; PATHARE, Pradip M</creatorcontrib><description>Provided herein are injectable pharmaceutical formulations, methods for their production, kits, and uses thereof in the treatment of disorders such as mental disorders in subjects such as companion animals. The injectable pharmaceutical formulations include a psychopharmaceutical agent, a release modifier, and an aqueous vehicle. The pharmaceutical formulations allow for a time-restricted temporal controlled-release of the psychopharmaceutical agent upon administration by injection such as subcutaneous injection. The mental disorders treatable with the pharmaceutical formulations include those associated with a 5-HT2 receptor, such as anxiety disorders (e.g., separation anxiety, social anxiety, noise phobia, obsessive-compulsive disorder (OCD)) and depressive disorders. L'invention concerne des formulations pharmaceutiques injectables, des procédés de production, des trousses et leur utilisation dans le traitement de troubles tels que les troubles mentaux chez des sujets tels que les animaux de compagnie. Les formulations pharmaceutiques injectables comprennent un agent psychopharmaceutique, un modificateur de libération et un véhicule aqueux. Les formulations pharmaceutiques permettent une libération contrôlée temporelle limitée dans le temps de l'agent psychopharmaceutique lors de l'administration par injection, par exemple sous-cutanée. Les troubles mentaux pouvant être traités par les formulations pharmaceutiques comprennent ceux associés à un récepteur 5-HT2, tels que les troubles anxieux (p. ex., l'anxiété de séparation, l'anxiété sociale, la phobie du bruit, les troubles obsessionnels compulsifs [TOC]) et les troubles dépressifs.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20241212&amp;DB=EPODOC&amp;CC=WO&amp;NR=2024251807A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20241212&amp;DB=EPODOC&amp;CC=WO&amp;NR=2024251807A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SHUKOOR, Mohammed I</creatorcontrib><creatorcontrib>MORGAN, Michael E</creatorcontrib><creatorcontrib>VARTY, Geoffrey B</creatorcontrib><creatorcontrib>DRYSDALE, Doug</creatorcontrib><creatorcontrib>PALFREYMAN, Michael</creatorcontrib><creatorcontrib>NIVOROZHKIN, Alex</creatorcontrib><creatorcontrib>AVERY, Kenneth L</creatorcontrib><creatorcontrib>FENG, Ju</creatorcontrib><creatorcontrib>PATHARE, Pradip M</creatorcontrib><title>COMPANION ANIMAL TREATMENTS</title><description>Provided herein are injectable pharmaceutical formulations, methods for their production, kits, and uses thereof in the treatment of disorders such as mental disorders in subjects such as companion animals. The injectable pharmaceutical formulations include a psychopharmaceutical agent, a release modifier, and an aqueous vehicle. The pharmaceutical formulations allow for a time-restricted temporal controlled-release of the psychopharmaceutical agent upon administration by injection such as subcutaneous injection. The mental disorders treatable with the pharmaceutical formulations include those associated with a 5-HT2 receptor, such as anxiety disorders (e.g., separation anxiety, social anxiety, noise phobia, obsessive-compulsive disorder (OCD)) and depressive disorders. L'invention concerne des formulations pharmaceutiques injectables, des procédés de production, des trousses et leur utilisation dans le traitement de troubles tels que les troubles mentaux chez des sujets tels que les animaux de compagnie. Les formulations pharmaceutiques injectables comprennent un agent psychopharmaceutique, un modificateur de libération et un véhicule aqueux. Les formulations pharmaceutiques permettent une libération contrôlée temporelle limitée dans le temps de l'agent psychopharmaceutique lors de l'administration par injection, par exemple sous-cutanée. Les troubles mentaux pouvant être traités par les formulations pharmaceutiques comprennent ceux associés à un récepteur 5-HT2, tels que les troubles anxieux (p. ex., l'anxiété de séparation, l'anxiété sociale, la phobie du bruit, les troubles obsessionnels compulsifs [TOC]) et les troubles dépressifs.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJB29vcNcPTz9PdTAJK-jj4KIUGujiG-rn4hwTwMrGmJOcWpvFCam0HZzTXE2UM3tSA_PrW4IDE5NS-1JD7c38jAyMTI1NDCwNzR0Jg4VQDehSGN</recordid><startdate>20241212</startdate><enddate>20241212</enddate><creator>SHUKOOR, Mohammed I</creator><creator>MORGAN, Michael E</creator><creator>VARTY, Geoffrey B</creator><creator>DRYSDALE, Doug</creator><creator>PALFREYMAN, Michael</creator><creator>NIVOROZHKIN, Alex</creator><creator>AVERY, Kenneth L</creator><creator>FENG, Ju</creator><creator>PATHARE, Pradip M</creator><scope>EVB</scope></search><sort><creationdate>20241212</creationdate><title>COMPANION ANIMAL TREATMENTS</title><author>SHUKOOR, Mohammed I ; MORGAN, Michael E ; VARTY, Geoffrey B ; DRYSDALE, Doug ; PALFREYMAN, Michael ; NIVOROZHKIN, Alex ; AVERY, Kenneth L ; FENG, Ju ; PATHARE, Pradip M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2024251807A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2024</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SHUKOOR, Mohammed I</creatorcontrib><creatorcontrib>MORGAN, Michael E</creatorcontrib><creatorcontrib>VARTY, Geoffrey B</creatorcontrib><creatorcontrib>DRYSDALE, Doug</creatorcontrib><creatorcontrib>PALFREYMAN, Michael</creatorcontrib><creatorcontrib>NIVOROZHKIN, Alex</creatorcontrib><creatorcontrib>AVERY, Kenneth L</creatorcontrib><creatorcontrib>FENG, Ju</creatorcontrib><creatorcontrib>PATHARE, Pradip M</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SHUKOOR, Mohammed I</au><au>MORGAN, Michael E</au><au>VARTY, Geoffrey B</au><au>DRYSDALE, Doug</au><au>PALFREYMAN, Michael</au><au>NIVOROZHKIN, Alex</au><au>AVERY, Kenneth L</au><au>FENG, Ju</au><au>PATHARE, Pradip M</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMPANION ANIMAL TREATMENTS</title><date>2024-12-12</date><risdate>2024</risdate><abstract>Provided herein are injectable pharmaceutical formulations, methods for their production, kits, and uses thereof in the treatment of disorders such as mental disorders in subjects such as companion animals. The injectable pharmaceutical formulations include a psychopharmaceutical agent, a release modifier, and an aqueous vehicle. The pharmaceutical formulations allow for a time-restricted temporal controlled-release of the psychopharmaceutical agent upon administration by injection such as subcutaneous injection. The mental disorders treatable with the pharmaceutical formulations include those associated with a 5-HT2 receptor, such as anxiety disorders (e.g., separation anxiety, social anxiety, noise phobia, obsessive-compulsive disorder (OCD)) and depressive disorders. L'invention concerne des formulations pharmaceutiques injectables, des procédés de production, des trousses et leur utilisation dans le traitement de troubles tels que les troubles mentaux chez des sujets tels que les animaux de compagnie. Les formulations pharmaceutiques injectables comprennent un agent psychopharmaceutique, un modificateur de libération et un véhicule aqueux. Les formulations pharmaceutiques permettent une libération contrôlée temporelle limitée dans le temps de l'agent psychopharmaceutique lors de l'administration par injection, par exemple sous-cutanée. Les troubles mentaux pouvant être traités par les formulations pharmaceutiques comprennent ceux associés à un récepteur 5-HT2, tels que les troubles anxieux (p. ex., l'anxiété de séparation, l'anxiété sociale, la phobie du bruit, les troubles obsessionnels compulsifs [TOC]) et les troubles dépressifs.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre
recordid cdi_epo_espacenet_WO2024251807A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title COMPANION ANIMAL TREATMENTS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T15%3A22%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SHUKOOR,%20Mohammed%20I&rft.date=2024-12-12&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2024251807A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true